Prevention & Risk Reduction: A key FDA approval | AI model detects diabetes risk | Insulin syringes recalled

The medication is approved for slowing CKD progression in patients with type 2 diabetes. It can also reduce a patient's risk of heart failure hospitalization and cardiovascular death. 

In addition, the team reported, an EPA monotherapy appears to be more beneficial than a mix of EPA and DHA.

Researchers in Japan are focused on uncovering new data on the body's response to a high-fat diet, hoping their work can lead to improved treatment options in the future. 

The expert analysis includes insights taken from observational studies and large clinical trials.

The algorithm measures the amount of fat surrounding a person's heart, using that information to create an accurate diabetes risk assessment. 

Researchers will provide a full breakdown of the study's findings in August. 

Regularly eating a Southern-style diet full of added fats, fried foods, processed meats and sugar-sweetened beverages can do harm to a person's cardiovascular system. 

Full results of the SURPASS-1 clinical trial were presented at the American Diabetes Association’s 81st Scientific Sessions.

The study's authors called for additional research in this area, noting that it may be beneficial to screen all heart failure patients for cancer. 

The study's authors examined data from more than 21,000 participants. 

This is a Class I recall, which means the issue could lead to serious injury or death.

This was found to be true for patients taking both hydrophilic and lipophilic statins.